HOXB9 and central nervous system cancer: Similarly, compared with those in low‐grade glioma samples (WHO I–II), EGR1 and HOXB9 levels were also significantly increased in high‐grade (WHO III–IV) glioma samples (0.463 ± 0.026 vs. 0.249 ± 0.013, 0.543 ± 0.018 vs. 0.233 ± 0.015; *p < 0.05; Figure 3A,C).